Full-Time

Associate Manufacturing Scientist I

Confirmed live in the last 24 hours

Arrowhead Pharmaceuticals

Arrowhead Pharmaceuticals

501-1,000 employees

Develops RNAi-based therapies for diseases

Compensation Overview

$58k - $68k/yr

Entry, Junior, Mid

Fitchburg, WI, USA

Category
Lab & Research
Medical Research
Requirements
  • BS or MS in chemistry, biochemistry, engineering, or related scientific field
  • Entry level to 5 years experience in a similar position
  • Experience working in a GMP setting and controlled documentation
  • Good verbal and written communication skills
  • Ability to work in a team environment
  • Ability to pay attention to detail
Responsibilities
  • Follow batch records, SOPs, and work instructions to detail
  • Document all operations in batch records and notebooks
  • Comply with GMP protocols
  • Assist other chemists within the CMC group during synthesis and chromatography of oligonucleotides including:
  • Reagent solution preparation
  • Column Packing
  • Mobile phase preparation
  • Fraction collection
  • Operate TFF to desalt purified RNA solutions
  • Operate a lyophilizer and package solid drug substance
  • Execute processes as part of a team to ensure production timelines are kept and quality product is produced
  • Maintain a clean work space
  • Maintain safety by wearing required personal protective equipment
Arrowhead Pharmaceuticals

Arrowhead Pharmaceuticals

View

Arrowhead Pharmaceuticals develops medicines aimed at treating severe diseases by targeting and silencing the genes responsible for them. The company uses RNA interference (RNAi), a natural process that reduces the expression of specific genes, to achieve effective treatment outcomes. This method allows for significant reduction of target genes, which can help stop or reverse the progression of diseases like cystic fibrosis and hepatitis B. Arrowhead stands out from competitors by focusing specifically on RNAi-based therapies and leveraging a strong portfolio of RNA chemistries and delivery methods. The company's goal is to address unmet medical needs and provide new treatment options for genetic disorders, generating revenue through partnerships, licensing agreements, and potential direct sales of approved therapies.

Company Size

501-1,000

Company Stage

IPO

Headquarters

Pasadena, California

Founded

2004

Simplify Jobs

Simplify's Take

What believers are saying

  • Arrowhead's collaboration with Sarepta includes a $500M upfront payment for RNA drug development.
  • Positive Phase 2 data for plozasiran boosts Arrowhead's credibility in treating hypertriglyceridemia.
  • Strategic financing with Sixth Street provides capital to advance Arrowhead's research pipeline.

What critics are saying

  • Increased competition from companies like Alnylam may impact Arrowhead's market share.
  • Potential regulatory scrutiny could delay Arrowhead's clinical trials for RNAi therapies.
  • Reliance on strategic financing may lead to increased debt obligations for Arrowhead.

What makes Arrowhead Pharmaceuticals unique

  • Arrowhead uses RNAi to target and silence disease-causing genes effectively.
  • The company has a broad portfolio of RNA chemistries for diverse therapeutic applications.
  • Arrowhead's strategic partnerships enhance its capabilities in developing innovative RNAi therapies.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

Life Insurance

Disability Insurance

401(k) Retirement Plan

Paid Vacation

Paid Sick Leave

Company News

BioSpace
Apr 15th, 2025
Arrowhead Pharmaceuticals Appoints Daniel Apel as Chief Financial Officer

Mr. Apel joins the company from Walgreens Boots Alliance, where he served as Global Head of Financial Planning and Analysis from 2019 through 2024.

PharmaData
Mar 1st, 2025
Arrowhead Pharmaceuticals Launches FCS Patient Resources on Rare Disease Day

Arrowhead Pharmaceuticals launches FCS patient resources on Rare Disease Day.

Business Wire
Feb 28th, 2025
Arrowhead Pharmaceuticals Launches on Rare Disease Day New Patient-Centric Resources for Those Affected by Familial Chylomicronemia Syndrome (FCS)

New Patient Resource Hub: Arrowhead expands its We'll Get There Soon campaign with the launch of a dedicated patient website, providing education, tools, and support for those living with FCS and extremely high triglycerides

World Pharmaceuticals
Nov 29th, 2024
Dev4All and Pharmaseed enter commercial partnership for preclinical R&D

Recently, Arrowhead Pharmaceuticals and Sarepta Therapeutics signed a global licensing and collaboration agreement to develop clinical and preclinical programmes.

BioSpace
Nov 26th, 2024
Sarepta Aims Up to $10B at Arrowhead to Diversify Pipeline With RNA Drugs

Sarepta Therapeutics is putting massive biobucks on the line to work on RNA drugs with Arrowhead, paying out $500 million upfront to find new treatments for rare genetic diseases of the muscle, central nervous system and lung.